Thus, low-dose IL-2 accompanied with tocilizumab may be an alternative treatment for the patients in the active stage of SLE who fail to respond to initial antibiotics and high-dose glucocorticoids. The gene discussed is IL2; the disease is systemic lupus erythematosus.